JB/CALL/COSMO PHARMACEUTICALS/50/0.05/20.12.24 Share Price

Warrant

COYOJB

CH1272326617

Market Closed - Swiss Exchange 16:20:00 10/05/2024 BST
1.049 CHF -2.60% Intraday chart for JB/CALL/COSMO PHARMACEUTICALS/50/0.05/20.12.24
Current month-9.33%
1 month-0.10%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change Volume
10/05/24 1.049 -2.60% 0
08/05/24 1.077 -3.32% 0
07/05/24 1.114 -1.42% 0
06/05/24 1.13 +1.16% 0
03/05/24 1.117 +1.92% 0

Delayed Quote Swiss Exchange

Last update May 10, 2024 at 04:20 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying COSMO PHARMACEUTICALS N.V.
Issuer Bank Julius Bär
COYOJB
ISINCH1272326617
Date issued 09/06/2023
Strike 50 CHF
Maturity 20/12/2024 (224 Days)
Parity 20 : 1
Emission price 0.34 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 1.265 CHF
Lowest since issue 0.044 CHF
Spread 0.015 CHF
Spread %1.43%

Company Profile

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Sector
-
More about the company

Ratings for Cosmo Pharmaceuticals N.V.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Cosmo Pharmaceuticals N.V.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
72.5 EUR
Average target price
94.95 EUR
Spread / Average Target
+30.98%
Consensus
  1. Stock Market
  2. Warrants
  3. COYOJB Warrant